ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 11.6% according to JP Morgan.
JP Morgan set a target price of 323 GBX for the company, which when compared to the ConvaTec Group PLC share price of 289 GBX at opening today (22/03/2024) indicates a potential upside of 11.6%. Trading has ranged between 195 (52 week low) and 291 (52 week high) with an average of 6,238,975 shares exchanging hands daily. The market capitalisation at the time of writing is £5,954,807,018.
Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care includes advanced solutions for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories and personalized services for individuals with a stoma. Its Continence and Critical Care includes products and services for people with urinary continence issues, and other devices for critical care. Its Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.
ConvaTec Group PLC 11.6% potential upside indicated by JP Morgan
- Written by: Charlotte Edwards
Latest Company News
Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The programme, managed by UBS AG London Branch, will run until 31 December 2025 and aims to reduce the company’s share capital, with purchased shares either cancelled or held in treasury for employee plans.
Convatec Group Plc celebrates the CMS's postponement of LCDs for diabetic foot ulcers, ensuring continued access to their trusted InnovaMatrix® for Medicare patients.
Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings.
ConvaTec Group plc (LON:CTEC) reports strong annual results with 7.2% organic revenue growth, margin expansion and new product launches.
